Picture of PDS Biotechnology logo

PDSB — PDS Biotechnology Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Momentum

Relative Strength (%)
1m+5.99%
3m-22.47%
6m-31.84%
1yr-61.73%
Volume Change (%)
10d/3m-51.16%
Price vs... (%)
52w High-77.48%
50d MA-8.95%
200d MA-47.53%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-47.96%
Return on Equity-55.69%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for PDSB

After a strong run, what's next for investors in Pds Biotechnology? background image

After a strong run, what's next for investors in Pds Biotechnology?

If you've ever found yourself feeling increasingly drawn to a stock that's constantly rising in price, you are not alone...  Since the dawn of the stock market, speculators have been captured by the tendency of prices to 'trend'.  When...

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of PDS Biotechnology EPS forecast chart

Profile Summary

PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is engaged in the developing a pipeline of molecularly targeted immunotherapies. The Company owns the T-cell activating platforms designed to train the immune system to attack and destroy disease; Versamune, for treatments in oncology and Infectimune, for treatments in infectious disease. Infectimune is also designed to promote the induction of disease-specific neutralizing antibodies. Its immuno-oncology product candidates are of potential interest for use as a component of combination product candidates to provide treatments across a range of advanced and/or refractory cancers. It develops targeted product candidates to treat several cancers, including Human Papillomavirus (HPV) associated cancers, melanoma, colorectal, lung, breast and prostate cancers. Its infectious disease candidates are of potential interest as vaccines to prevent COVID-19 and universal influenza.

Directors

Last Annual
December 31st, 2021
Last Interim
March 31st, 2022
Incorporated
January 22nd, 2009
Public Since
October 1st, 2015
No. of Shareholders
44
No. of Employees
22
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
28,450,894

PDSB Share Price Performance

Upcoming Events for PDSB

Q2 2022 PDS Biotechnology Corp Earnings Release

Q3 2022 PDS Biotechnology Corp Earnings Release

Similar to PDSB

Picture of 180 Life Sciences logo

180 Life Sciences

us flag iconNASDAQ Capital Market

Picture of 9 Meters Biopharma logo

9 Meters Biopharma

us flag iconNASDAQ Capital Market

Picture of Abeona Therapeutics logo

Abeona Therapeutics

us flag iconNASDAQ Capital Market

Picture of ABVC Biopharma logo

ABVC Biopharma

us flag iconNASDAQ Capital Market

Picture of Acer Therapeutics logo

Acer Therapeutics

us flag iconNASDAQ Capital Market

FAQ

Or unlock with your email

Or unlock with your email